Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01449279 · ClinicalTrials.gov registry record · Phase 2
Pilot Ipilimumab in Stage IV Melanoma Receiving Palliative Radiation Therapy
A Phase 2 study, sponsored by Stanford University.
- Completed
- Registry status
- Phase 2
- Development phase
- 22
- Enrollment target
NCT01449279: Completed Phase 2 study, sponsored by Stanford University.
NCT01449279 is a Phase 2 study that has completed, run by Stanford University. The registered enrollment target is 22 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01449279, a Phase 2 study, has completed, sponsored by Stanford University.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 22 participants
- Enrollment target
Study Summary
To determine the safety of local palliative radiation therapy used in combination with anti-CTLA-4 immunotherapy.
Interventions
- DRUG Ipilimumab
- RADIATION Radiation Therapy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 22 participants |
| Start Date | 2011-10 |
| Est. Completion | 2016-12-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01449279
The ClinicalTrials.gov registry entry for NCT01449279 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 22 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Stanford University, which has 1,744 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Ipilimumab is the first listed.
NCT01449279 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01449279 about?
NCT01449279 is a clinical study titled "Pilot Ipilimumab in Stage IV Melanoma Receiving Palliative Radiation Therapy". To determine the safety of local palliative radiation therapy used in combination with anti-CTLA-4 immunotherapy.
What is the current status of trial NCT01449279?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 22 participants. The study started on 2011-10. Estimated completion is 2016-12-01.
What interventions are being tested in trial NCT01449279?
The interventions under investigation include: Ipilimumab (DRUG), Radiation Therapy (RADIATION).
Who is sponsoring clinical trial NCT01449279?
This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.